SEC Form 4 · accession 0001209191-15-084824
Anacor Pharmaceuticals, Inc. · ANAC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Vincent P Ippolito
Officer — EVP & Chief Commercial Officer
Period of report
Dec 9, 2015
Accepted (ET)
Dec 11, 2015 · 7:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001411158
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 9, 2015 | M | 20,000 | $19.96 | A | 91,840 | D | |
| Common StockF3 | Dec 9, 2015 | S | 17,270 | $107.8547 | D | 74,570 | D | |
| Common StockF4 | Dec 9, 2015 | S | 2,730 | $108.22 | D | 71,840 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F5 | $19.96 | Dec 9, 2015 | M | 20,000 | D | — | Mar 6, 2024 | Common Stock | 20,000 | 81,000 | D |
Explanation of responses
- F1Includes shares purchased in 2015 pursuant to the Issuer's ESPP.
- F2This sale was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the Reporting Person.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.12 to $108.11, inclusive.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.12 to $108.80, inclusive.
- F5The award is subject to a four-year vesting period, with 25% of the shares subject to the award vesting in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting each month thereafter. The Vesting Commencement Date was February 28, 2014.